Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Jaimie Z. Shing, Pamela C. Hull, Yuwei Zhu, Julia W. Gargano, Lauri E. Markowitz, Angela A. Cleveland, Manideepthi Pemmaraju, Ina U. Park, Erin Whitney, Edward F. Mitchel, Marie R. Griffin

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalPapillomavirus Research
Volume7
DOIs
StatePublished - Jun 2019

Bibliographical note

Publisher Copyright:
© 2019

Funding

This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention , and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences , National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention, and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences, National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. The authors thank the Tennessee Division of TennCare of the Department of Finance and Administration for providing the data, and Dr. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, for providing careful review and helpful comments.

FundersFunder number
Centers for Disease Control and Prevention
National Center for Advancing Translational Sciences (NCATS)TL1TR002244
National Center for Advancing Translational Sciences (NCATS)

    Keywords

    • Anogenital warts
    • HPV vaccination
    • Impact
    • Trend

    ASJC Scopus subject areas

    • Virology
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination'. Together they form a unique fingerprint.

    Cite this